Afatinib Dimaleate interactions
Checked as Afatinib in this data source.
Full monograph for Afatinib DimaleateCheck it against another medicine
Medicines
95 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Abiraterone Acetate | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Alpelisib | Moderate | Others | Coadministration of inhibitors of the breast cancer resistance protein (BCRP) transporter with alpelisib may increase the plasma concentrations and risk of… | 3 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Apalutamide | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Asciminib | Moderate | Distribution | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 1 sources — open the full entry |
| Azithromycin DihydratebaseOphthalmic | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Brigatinib | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Cabozantinib | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Carbamazepine | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Clarithromycin | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Crizotinib | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Daclatasvir | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Daclatasvir + Sofosbuvir | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Darolutamide | Moderate | Metabolism | Coadministration with darolutamide may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP)… | 3 sources — open the full entry |
| Dexamethasone | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Dexamethasone + Levofloxacin | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Dexamethasone + Tobramycin | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Diltiazem Hydrochloride | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Efavirenz | Moderate | Synergy | Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Efavirenz has been associated with… | 7 sources — open the full entry |
| Elacestrant | Moderate | Distribution | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 1 sources — open the full entry |
| Elagolix Sodium | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Enasidenib | Moderate | Distribution | Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion… | 3 sources — open the full entry |
| Enzalutamide | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Epirubicin Hydrochloride | Moderate | Synergy | The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes… | 4 sources — open the full entry |
| Erdafitinib | Moderate | Distribution | Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| ErythromycinLotionOral | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Flibanserin | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Fosphenytoin Sodium | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Furosemide + Spironolactone | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Moderate | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may decrease the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 6 sources — open the full entry |
| Gilteritinib Fumarate | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Glecaprevir + Pibrentasvir | Moderate | Distribution · Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter.3 documented mechanisms | 5 sources — open the full entry |
| Ibrutinib | Moderate | Absorption | Coadministration with ibrutinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. In vitro… | 21 sources — open the full entry |
| Istradefylline | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Itraconazole | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Ketoconazole | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| L-Asparginase | Moderate | Synergy | Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal… | 13 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Lapatinib | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Lasmiditan Hemisuccinate | Moderate | Distribution | Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer… | 1 sources — open the full entry |
Food & lifestyle
high-fat foods
ModerateAbsorption
Food may reduce the oral bioavailability of afatinib. According to the product labeling, administration of afatinib with a high-fat meal decreased peak plasma concentration (Cmax) by 50% and systemic exposure (AUC) by 39% compared to administration in the fasted state.
What to do: Afatinib should be taken at least 1 hour before or 2 hours after a meal.
1 source
- "Product Information. Gilotrif (afatinib)." Boehringer Ingelheim (2013):
Conditions
Conditions in which Afatinib Dimaleate needs care, as documented in this source.
Lung Diseases
ModerateThe use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, permanently discontinue these agents and institute appropriate measures. Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.
7 sources
- "Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals (2011):
- "Product Information. Zelboraf (vemurafenib)." Genentech (2011):
- "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group (2011):
- "Product Information. Mekinist (trametinib)." GlaxoSmithKline (2013):
- "Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals (2014):
- "Product Information. Zydelig (idelalisib)." Gilead Sciences (2014):
- "Product Information. Alecensa (alectinib)." Genentech (2015):